NCT00861627 - Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2015

Conditions

Carcinoma, Non-small Cell Lung

Interventions

BIOLOGICAL

REOLYSIN®

3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle

DRUG

Carboplatin

5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle

DRUG

Paclitaxel

175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle

Trial Locations (2)

Georgetown University Medical Center, Washington D.C.

The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Columbus